Health Trials

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

ConditionsMelanoma Stage IIIB-cell Non Hodgkin LymphomaPediatric ALLChildhood Non-Hodgkin LymphomaAcute Lymphatic LeukemiaChronic Lymphatic LeukemiaMelanoma Stage IV
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorMiltenyi Biomedicine GmbH

About this trial

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Eligibility criteria

Qualifiers

Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.

Patient has provided informed consent prior to enrollment.

Disqualifiers

No exclusion criteria

Trial design

Treatments tested in this trial

  • MB-CART19.1
  • MB-CART20.1
  • MB-CART2019.1

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Miltenyi Biomedicine GmbH

Lead sponsor

Source ClinicalTrials.gov